LAWRENCEVILLE, N.J.,
July 1, 2015 /PRNewswire/
-- Celsion Corporation (NASDAQ: CLSN), an oncology drug
development company, today announced that Michael H. Tardugno, Chairman, President and
CEO, is scheduled to present at the Cantor Fitzgerald's Inaugural
Healthcare Conference on Wednesday, July 8,
2015, at 4:15 p.m. Eastern
Time. The conference is being held at Le Parker
Meridien Hotel located at 119 W. 56th Street, New York NY 10019.
A copy of the presentation will be available in the Events &
Presentations section of the Company's website at
www.celsion.com.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on
developing a portfolio of innovative cancer treatments, including
directed chemotherapies, immunotherapies and RNA- or DNA-based
therapies. The Company's lead program is ThermoDox®, a proprietary
heat-activated liposomal encapsulation of doxorubicin, currently in
Phase III development for the treatment of primary liver cancer and
in Phase II development for the treatment of recurrent chest wall
breast cancer. The pipeline also includes GEN-1, a DNA-based
immunotherapy for the localized treatment of ovarian and brain
cancers. Celsion has three platform technologies for the
development of novel nucleic acid-based immunotherapies and other
anti-cancer DNA or RNA therapies, including TheraPlas™,
TheraSilence™ and RAST™. For more information on Celsion, visit our
website: http://www.celsion.com.
Celsion wishes to inform readers that forward-looking
statements in this release are made pursuant to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of
1995. Readers are cautioned that such forward-looking
statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and
development activities and in clinical trials; FDA and regulatory
uncertainties and risks; the significant expense, time, and risk of
failure of conducting clinical trials; the need for Celsion to
evaluate its future development plans; possible acquisitions or
licenses of other technologies, assets or businesses or the
possible failure to make such acquisitions or licenses; possible
actions by customers, suppliers, competitors, regulatory
authorities; and other risks detailed from time to time in the
Celsion's periodic reports and prospectuses filed with the
Securities and Exchange Commission. Celsion assumes no obligation
to update or supplement forward-looking statements that become
untrue because of subsequent events, new information or
otherwise.
Celsion Investor Contact
Jeffrey W. Church
Senior Vice President and CFO
609-482-2455
jchurch@celsion.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/celsion-corporation-to-present-at-cantor-fitzgeralds-inaugural-healthcare-conference-on-july-8-2015-300107411.html
SOURCE Celsion Corporation